Skip to main content
PMC home page
The Texas Heart Institute Journal logoLink to The Texas Heart Institute Journal
. 1997;24(2):81–89.

Chelation therapy for cardiovascular disease. Review and commentary.

M R Lewin
PMCID: PMC325409  PMID: 9205980

Full text

PDF
85

Images in this article

87Image
on p.87

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allain P., Mauras Y., Premel-Cabic A., Islam S., Herve J. P., Cledes J. Effects of an EDTA infusion on the urinary elimination of several elements in healthy subjects. Br J Clin Pharmacol. 1991 Mar;31(3):347–349. doi: 10.1111/j.1365-2125.1991.tb05541.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BELLIN J., LASZLO D. Metabolism and removal of Ca45 in man. Science. 1953 Mar 27;117(3039):331–334. doi: 10.1126/science.117.3039.331. [DOI] [PubMed] [Google Scholar]
  3. BESSMAN S. P., RIED H., RUBIN M. Treatment of lead encephalopathy with calcium disodium versenate; report of a case. Med Ann Dist Columbia. 1952 Jun;21(6):312–315. [PubMed] [Google Scholar]
  4. CLARKE C. N., CLARKE N. E., MOSHER R. E. Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid. Am J Med Sci. 1956 Dec;232(6):654–666. doi: 10.1097/00000441-195612000-00006. [DOI] [PubMed] [Google Scholar]
  5. CLARKE N. E., CLARKE C. N., MOSHER R. E. The in vivo dissolution of metastatic calcium; an approach to atherosclerosis. Am J Med Sci. 1955 Feb;229(2):142–149. doi: 10.1097/00000441-195502000-00004. [DOI] [PubMed] [Google Scholar]
  6. CLARKE N. E., Sr, CLARKE N. E., Jr, MOSHER R. E. Treatment of occlusive vascular disease with disodium ethylene diamine tetraacetic acid (EDTA). Am J Med Sci. 1960 Jun;239:732–744. doi: 10.1097/00000441-196006000-00008. [DOI] [PubMed] [Google Scholar]
  7. Cole D., St George I. Medicine at the fringes. N Z Med J. 1993 Apr 14;106(953):130–133. [PubMed] [Google Scholar]
  8. Conti C. R. Chelation therapy for atherosclerosis: one man's view. Clin Cardiol. 1995 Oct;18(10):545–545. doi: 10.1002/clc.4960181002. [DOI] [PubMed] [Google Scholar]
  9. Eisenberg D. M., Kessler R. C., Foster C., Norlock F. E., Calkins D. R., Delbanco T. L. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med. 1993 Jan 28;328(4):246–252. doi: 10.1056/NEJM199301283280406. [DOI] [PubMed] [Google Scholar]
  10. FOREMAN H., FUQUA P. A., NORWOOD W. D. Experimental administration of ethylenediamine-tetraacetic acid in plutonium poisoning. AMA Arch Ind Health. 1954 Sep;10(3):226–231. [PubMed] [Google Scholar]
  11. GUBNER R. S., KALLMAN H. Treatment of digitalis toxicity by chelation of serum calcium. Am J Med Sci. 1957 Aug;234(2):136–144. doi: 10.1097/00000441-195708000-00002. [DOI] [PubMed] [Google Scholar]
  12. Godfrey M. E. EDTA chelation as a treatment of arteriosclerosis. N Z Med J. 1990 Apr 11;103(887):162–163. [PubMed] [Google Scholar]
  13. Grier M. T., Meyers D. G. So much writing, so little science: a review of 37 years of literature on edetate sodium chelation therapy. Ann Pharmacother. 1993 Dec;27(12):1504–1509. doi: 10.1177/106002809302701217. [DOI] [PubMed] [Google Scholar]
  14. Guldager B., Jelnes R., Jørgensen S. J., Nielsen J. S., Klaerke A., Mogensen K., Larsen K. E., Reimer E., Holm J., Ottesen S. EDTA treatment of intermittent claudication--a double-blind, placebo-controlled study. J Intern Med. 1992 Mar;231(3):261–267. doi: 10.1111/j.1365-2796.1992.tb00533.x. [DOI] [PubMed] [Google Scholar]
  15. HOLLAND J. F., DANIELSON E., SAHAGIAN-EDWARDS A. Use of ethylene diamine tetra acetic acid in hypercalcemic patients. Proc Soc Exp Biol Med. 1953 Nov;84(2):359–364. doi: 10.3181/00379727-84-20645. [DOI] [PubMed] [Google Scholar]
  16. Holohan T. V. Referral by default. The medical community and unorthodox therapy. JAMA. 1987 Mar 27;257(12):1641–1642. doi: 10.1001/jama.257.12.1641. [DOI] [PubMed] [Google Scholar]
  17. KITCHELL J. R., MELTZER L. E., SEVEN M. J. Potential uses of chelation methods in the treatment of cardiovascular diseases. Prog Cardiovasc Dis. 1961 Jan;3:338–349. doi: 10.1016/s0033-0620(61)90001-9. [DOI] [PubMed] [Google Scholar]
  18. KITCHELL J. R., PALMON F., Jr, AYTAN N., MELTZER L. E. The treatment of coronary artery disease with disodium EDTA. A reappraisal. Am J Cardiol. 1963 Apr;11:501–506. doi: 10.1016/0002-9149(63)90011-0. [DOI] [PubMed] [Google Scholar]
  19. LAMAR C. P. CHELATION THERAPY OF OCCLUSIVE ARTERIOSCLEROSIS IN DIABETIC PATIENTS. Angiology. 1964 Sep;15:379–395. doi: 10.1177/000331976401500902. [DOI] [PubMed] [Google Scholar]
  20. Lamar C. P. Chelation endarterectomy for occlusive atherosclerosis. J Am Geriatr Soc. 1966 Mar;14(3):272–294. doi: 10.1111/j.1532-5415.1966.tb05318.x. [DOI] [PubMed] [Google Scholar]
  21. Monaco G. P., Green S. Recognizing deception in the promotion of untested and unproven medical treatments. N Y State J Med. 1993 Feb;93(2):88–91. [PubMed] [Google Scholar]
  22. Murray R. H., Rubel A. J. Physicians and healers--unwitting partners in health care. N Engl J Med. 1992 Jan 2;326(1):61–64. doi: 10.1056/NEJM199201023260113. [DOI] [PubMed] [Google Scholar]
  23. Olszewer E., Carter J. P. EDTA chelation therapy in chronic degenerative disease. Med Hypotheses. 1988 Sep;27(1):41–49. doi: 10.1016/0306-9877(88)90082-5. [DOI] [PubMed] [Google Scholar]
  24. Ornish D. Can lifestyle changes reverse coronary heart disease? World Rev Nutr Diet. 1993;72:38–48. doi: 10.1159/000422326. [DOI] [PubMed] [Google Scholar]
  25. Ornish D., Scherwitz L. W., Doody R. S., Kesten D., McLanahan S. M., Brown S. E., DePuey E., Sonnemaker R., Haynes C., Lester J. Effects of stress management training and dietary changes in treating ischemic heart disease. JAMA. 1983 Jan 7;249(1):54–59. [PubMed] [Google Scholar]
  26. PAGE I. H. Atherosclerosis; an introduction. Circulation. 1954 Jul;10(1):1–27. doi: 10.1161/01.cir.10.1.1. [DOI] [PubMed] [Google Scholar]
  27. RUBIN M., GIGNAC S., BESSMAN S. P., BELKNAP E. L. Enhancement of lead excretion in humans by disodium calcium ethylene-diamine tetraacetate. Science. 1953 Jun 12;117(3050):659–660. doi: 10.1126/science.117.3050.659. [DOI] [PubMed] [Google Scholar]
  28. SAPEIKA N. Antagonism of digitalis action by ethylenediamine tetraacetic acid. Arch Int Pharmacodyn Ther. 1954 Apr 1;97(3-4):373–378. [PubMed] [Google Scholar]
  29. SPENCER H., VANKINSCOTT V., LEWIN I., LASZLO D. Removal of calcium in man by ethylenediamine tetra-acetic acid. A metabolic study. J Clin Invest. 1952 Dec;31(12):1023–1027. doi: 10.1172/JCI102694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Tymianski M., Charlton M. P., Carlen P. L., Tator C. H. Properties of neuroprotective cell-permeant Ca2+ chelators: effects on [Ca2+]i and glutamate neurotoxicity in vitro. J Neurophysiol. 1994 Oct;72(4):1973–1992. doi: 10.1152/jn.1994.72.4.1973. [DOI] [PubMed] [Google Scholar]
  31. Tymianski M., Wallace M. C., Spigelman I., Uno M., Carlen P. L., Tator C. H., Charlton M. P. Cell-permeant Ca2+ chelators reduce early excitotoxic and ischemic neuronal injury in vitro and in vivo. Neuron. 1993 Aug;11(2):221–235. doi: 10.1016/0896-6273(93)90180-y. [DOI] [PubMed] [Google Scholar]
  32. Wynn J. E., Van't Riet B., Borzelleca J. F. The toxicity and pharmacodynamics of EGTA: oral administration to rats and comparisons with EDTA. Toxicol Appl Pharmacol. 1970 May;16(3):807–817. doi: 10.1016/0041-008x(70)90087-6. [DOI] [PubMed] [Google Scholar]

Articles from Texas Heart Institute Journal are provided here courtesy of Texas Heart Institute

RESOURCES